Table 2.
Demographic & Laboratory Results for Psoriasis Patients and Controls
| Psoriasis Median (IQR) n=4 |
Controls Median (IQR) n=4 |
p-value | Normal Values |
|
|---|---|---|---|---|
| Age | 50 (43–57) | 49 (43–52) | 0.66 | - |
| Male, count (%) | 3 (75%) | 3 (75%) | 1.00 | - |
| BSA, % | 12 (10.6–16) | - | - | - |
| Physician’s Global Assessment (PGA) | 2.2 (2.0–2.8) | - | - | - |
| Psoriasis Area Severity Index (PASI) | 8.4 (6.9–13.3) | - | - | - |
| Diagnosed psoriatic arthritis, count (%) | 0 (0%) | - | ||
| Tobacco use, count (%) | 0 (0%) | 0 (0%) | 1.00 | - |
| BMI | 26.9 (21.5–29.5) | 29.7 (28.5–29.9) | 0.22 | 18.5–24.9 |
| Fasting blood glucose | 94 (89–107) | 86 (72–96) | 0.23 | 70–99 mg/dL |
| Systolic blood pressure | 133 (123–142) | 124 (118–134) | 0.48 | 90–140 mmHg |
| Diastolic blood pressure | 81 (72–84) | 73 (69–80) | 0.56 | 60–90 mmHg |
| Diagnosed hypertension, count (%) | 1 (25%) | 1 (25%) | 1.00 | - |
| Antihypertensive therapy, count (%) | 0 (0%) | 1 (25%) | 1.00 | - |
| Total Cholesterol | 214 (182–225) | 188 (186–206)a | 0.66 | ≤200 mg/dL |
| Triglycerides | 120 (84–194) | 262 (165–290)a | 0.15 | ≤150 mg/dL |
| HDL | 45 (37–70) | 50 (18–66)a | 0.66 | ≥40 mg/dL |
| LDL | 105 (97–136) | 118 (62–123)a | 0.58 | ≤100 mg/dL |
| Statin therapy, count (%) | 1 (25%) | 0 (0%) | 1.00 | - |
| hsCRP | 2.9 (0.1–8.4)a | 1.5 (0.4–2.0) | 0.37 | ≤3.0 mg/L |
| ALT | 38 (18–68) | 31 (22–51) | 0.73 | 17–63 U/L |
| AST | 28 (19–43) | 41 (23–62) | 0.50 | 15–41 U/L |
| Alkaline phosphatase | 71 (56–92) | 71 (57–95) | 0.91 | 32–91 U/L |
| Total bilirubin | 0.8 (0.8–1.0) | 0.8 (0.6–1.0) | 0.52 | 0.3–1.2 mg/dL |
| Alcohol consumption, count (%) | ||||
| Non-drinker | 2 (50%) | 3 (75%) | 1.00 | - |
| Social drinker (<7 drinks/week) | 2 (50%) | 1 (25%) | - |
a
n=3
b
IQR – Interquartile Range; n/a – not available
c
Diabetes mellitus, a traditional cardiovascular risk factor, is excluded from this table as it was an exclusion criterion in this study.